UNSPSC 51322004: Colestipol

This classification denotes an anti-lipidemic agent with the molecular formula ((C3H5ClO)mon(C4H13N3)mon)co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K50N755924, chemically known as 1,2-ethanediamine, n-(2-aminoethyl)-n-(2-((2-aminoethyl)amino)ethyl)-, polymer with (chloromethyl)oxirane but generally known as colestipol, which bears US NIH Compound Identifier 62816. European Medicines Agency schedules Colestipol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01425MIG.

UNSPSC 51322004 Colestipol, a Commodity code, represents pharmaceutical procurement by state and local health agencies, primarily for emergency medical services and public health benefit programs. State and local governments solicit under this code to acquire specific branded or generic medications—including cardiovascular agents, emergency life support drugs, and over-the-counter products—for fire rescue departments, health benefit plans, and institutional healthcare facilities. Purchases are typically small-unit, recurring buys driven by formulary requirements, emergency response protocols, and managed-care cost control initiatives. Issuing bodies include municipal fire departments and city purchasing offices (as primary end-users), state health and human services commissions managing pharmacy benefit programs, and cooperative purchasing alliances representing multiple state and local members.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for advanced life support medications (Labetalol, Epinephrine, Adenosine, and Diltiazem)—a $40,000 annual contract with a Small Local Business Enterprise 5 percent bid discount—requiring delivery within ten calendar days and nine-month minimum shelf life at award. The Texas Health and Human Services Commission posted RFI HHS0017013 in early April 2026 to gauge vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels, signaling state-level interest in alternative distribution and pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited RFP S1070000015802 through March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating jurisdictions including Oregon, requiring manufacturer compliance with current Good Manufacturing Practices, Drug Supply Chain Security Act certification, and wholesale partnerships with AmerisourceBergen, Cardinal Health, or Morris & Dickson, with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.